(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxynaphthacene-5,12-dione hydrochloride;Doxorubicin hydrochloride;Doxorubicin, HCl; (8s-cis)-10-((3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxynaphthacene-5,12-dione hydrochloride; 

5,12-Naphthacenedione,7,8,9,10-tetrahydro-6,8,10,11-tetrahydroxy-8-(hydroxyacetyl)-1-methoxy-,(8S,10S)- (9CI); Adriamycinone; Doxorubicin aglycone;Doxorubicinone; 5,12-Naphthacenedione,8-glycoloyl-7,8,9,10-tetrahydro-6,8,10,11-tetrahydroxy-1-methoxy-, (8S,10S)-(8CI);5,12-Naphthacenedione,7,8,9,10-tetrahydro-6,8,10,11-tetrahydroxy-8-(2-hydroxyacetyl)-1-methoxy-,(8S,10S)-; Adriamycin aglycone; 5,12-Naphthacenedione,7,8,9,10-tetrahydro-6,8,10,11-tetrahydroxy-8-(hydroxyacetyl)-1-methoxy-,(8S-cis)-; Epirubicin aglycone; 

5,12-Naphthacenedione,10-[[3-(3-cyano-4-morpholinyl)-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-,(8S,10S)-;5,12-Naphthacenedione,10-[[3-(3-cyano-4-morpholinyl)-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-,(8S,10S)- (9CI); 3'-Deamino-3'-(3-cyano-4-morpholinyl)adriamycin;MRA-CN; 3'-Deamino-3'-(3-cyano-4-morpholinyl)doxorubicin; 

3'-Deamino-3'-(2''-pyrrolin-1''-yl)doxorubicin; 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-(2,3-dihydro-1H-pyrrol-1-yl)-a-L-lyxo-hexopyranosyl]oxy]-,(8S-cis)-; AN 201(pharmaceutical); AN 201;5,12-Naphthacenedione,7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-(2,3-dihydro-1H-pyrrol-1-yl)-a-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)-;5,12-Naphthacenedione,7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-(2,3-dihydro-1H-pyrrol-1-yl)-a-L-lyxo-hexopyranosyl]oxy]-,(8S,10S)- (9CI); 

Cyanomorpholinoadriamycin;Mra-CN;NSC 357704;BRN 6050053;MRA-CN isomer a, a:b = 93:7;3'-(3-Cyano-4-morpholinyl)-3'-deamino-adriamycin;3'-Deamino-3'-(3-cyano-4-morpholinyl)doxorubicin;cyanomorpholino doxorubicin;AC1L2O8V;Neuro_000195;CCRIS 5080;YIMDLWDNDGKDTJ-UHFFFAOYSA-N;(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-(3-cyanomorpholin-4-yl)-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside;5,12-Naphthacenedione, 10-((3-(3-cyano-4-morpholinyl)-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-;5,12-Naphthacenedione, 7,8,9,10-tetrahydro-10-((3-(3-cyanomorpholino)-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-8-(hydroxyacetyl)-1-methoxy-6,8,11-trihydroxy-, (8s-cis)-;88254-07-3;C32H34N2O12;MRA-CN isomer b, a:b=17:83;NSC639650;NSC639651;NSC-639650;NSC-639651;LS-94088;NCI60_013156;A 489;A-489;3'-(3-cyano-4-morpholinyl)-3'-deaminoadriamycin;D335F8F4BD369D6DAED5217130193378;3'-Deamino-3'-(3-cyano-4-morpholinyl) doxorubicin, isomer a;3'-Deamino-3'-(3-cyano-4-morpholinyl)doxorubicin, isomer b;4-[3-hydroxy-2-methyl-6-[[3,5,12-trihydroxy-3-(2-hydroxyacetyl)-10-methoxy-6,11-dioxo-2,4-dihydro-1H-tetracen-1-yl]oxy]oxan-4-yl]morpholine-3-carbonitrile;5,12-Naphthacenedione, 10-((3-(3-cyano-4-morpholinyl)-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)- 

Heptanedioic acid, mono[2-[4-[(2,6-dideoxy-2-fluoro-a-L-talopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]-2-oxoethyl]ester, (2S-cis)-; MEJ 2303; ME 2303; FAD 104; Fluoro-doxorubicin;Heptanedioicacid, mono[2-[(2S,4S)-4-[(2,6-dideoxy-2-fluoro-a-L-talopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]-2-oxoethyl]ester (9CI);Heptanedioic acid,1-[2-[(2S,4S)-4-[(2,6-dideoxy-2-fluoro-a-L-talopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]-2-oxoethyl]ester; 

(8S,10S)-10-[[3-(Leucylamino)-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-8-glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione;5,12-Naphthacenedione, 10-3-(2S)-2-amino-4-methyl-1-oxopentylamino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyloxy-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)-;L-Leucyldoxorubicin;leurubicin;(8S,10S)-10-[(3-L-Leucylamino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-8-glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione;N-leucyldoxorubicin;N-(L-Leucyl)doxorubicin;Leurubicin; 

N-[N-(4-Carboxybutyryl)-4(R)-hydroxy-L-prolyl-L-alanyl-L-seryl-L-cyclohexylglycyl-L-glutaminyl-L-seryl-L-leucyl]doxorubicin;L-377202; 

Triferric adriamycin; Triferric doxorubicin; LS-139850;(7S,9S)-7-[(2S,4R,5R,6R)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,
11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,
12-dione;iron(3+); AC1MJ49F; NSC-267703; 

AC1Q6JIS;(7S,9S)-7-[(2R,4S,5S,6S)-5-amino-4-hydroxy-6-methyloxan-2-yl]oxy-6,9,
11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,
12-dione; 10-((4-amino-2,4,6-trideoxy-|A-l-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-,(8s-cis)-;5,12-naphthacenedione; 4'-Amino-3'-hydroxy-doxorubicin; AC1L4LM3; AR-1G5781; 4'-Amino-3'-hydroxydoxorubicin; AR-1G5780;